Sartorius pumping over €100m into production network to support growth

By Dan Stanton contact

- Last updated on GMT

Image: iStock/florencemcginn
Image: iStock/florencemcginn

Related tags: Bioprocess solutions division, Investment

Sartorius will invest around 10% of its annual revenues into its manufacturing network to support continued double-digit growth of its bioprocessing equipment business.

For the first quarter 2016, Sartorius reported sales of €302m ($340m), up 17% on the same period last year driven by strong growth in the firm’s Bioprocess Solutions which focuses on single-use products for biomanufacturing.

The firm has now seen double digit y-o-y sales growth for six quarters in a row and is hoping to continue this strong demand for Sartorius’ Bioprocess Solutions Division” ​through investments in its production network.

For 2016 we plan to invest around 10% of sales - or more than €100m - essentially to expand our capacities across the world,”​ company spokesperson Andreas Theisen told Biopharma-Reporter.com.

While details of specific investments have not been revealed, he said there were already plans to expand instrument production at the firm’s headquarters in Göttingen, Germany, as well as adding filter and bag capacity at its plant in Puerto Rico.

CEO Joachim Kreuzburg added some colour during a conference call to discuss results:

“In Puerto Rico, I think it will be a figure that we will invest here for the full year, let's say, around $15m probably,”​ whereas investment in Germany will be roughly double this, he told investors.

Facilities in China and Korea will also be expanded, though Kreuzburg said these would be at a much smaller scale. “We are not building new buildings there, rather adding equipment, installations etc into our existing buildings.”

Sartorius’s bioprocessing business has also grown by inorganic growth, through the addition of acquisitions BioOutsource​ and Cellca​ last April and July, respectively.

“We are very happy so far with the development of these businesses, both are growing at double-digit rate,”​ Kreuzburg said. 

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars